» Articles » PMID: 1535557

The Mdm-2 Oncogene Product Forms a Complex with the P53 Protein and Inhibits P53-mediated Transactivation

Overview
Journal Cell
Publisher Cell Press
Specialty Cell Biology
Date 1992 Jun 26
PMID 1535557
Citations 1067
Authors
Affiliations
Soon will be listed here.
Abstract

A cellular phosphoprotein with an apparent molecular mass of 90 kd (p90) that forms a complex with both mutant and wild-type p53 protein has been characterized, purified, and identified. The protein was identified as a product of the murine double minute 2 gene (mdm-2). The mdm-2 gene enhances the tumorigenic potential of cells when it is overexpressed and encodes a putative transcription factor. To determine if mdm-2 could modulate p53 transactivation, a p53-responsive element from the muscle creatine kinase gene was employed. A wild-type p53-expressing plasmid enhanced the expression of the p53-responsive element when cotransfected into cells that contain no endogenous p53. When a cosmid expressing mdm-2 was transfected with this p53-expressing plasmid, the transactivation of the p53-responsive element was inhibited. Thus, a product of the mdm-2 oncogene forms a tight complex with the p53 protein, and the mdm-2 oncogene can inhibit p53-mediated transactivation.

Citing Articles

Loss-of-function mutations in the dystonia gene THAP1 impair proteasome function by inhibiting PSMB5 expression.

Ramage D, Grant D, Timms R Nat Commun. 2025; 16(1):1511.

PMID: 39929834 PMC: 11811203. DOI: 10.1038/s41467-025-56782-1.


Citrullination at the N-terminal region of MDM2 by the PADI4 enzyme.

Neira J, Rizzuti B, Palomino-Schatzlein M, Rejas V, Abian O, Velazquez-Campoy A Protein Sci. 2025; 34(2):e70033.

PMID: 39840810 PMC: 11751894. DOI: 10.1002/pro.70033.


Raman active diyne-girder conformationally constrained p53 stapled peptides bind to MDM2 for visualisation without fluorophores.

Morgan D, McDougall L, Knuhtsen A, Buetow L, Steven C, Shepperson O RSC Chem Biol. 2025; 6(3):394-403.

PMID: 39830683 PMC: 11741006. DOI: 10.1039/d4cb00288a.


Inducing apoptosis in acute myeloid leukemia; mechanisms and limitations.

Koolivand Z, Bahreini F, Rayzan E, Rezaei N Heliyon. 2025; 11(1):e41355.

PMID: 39811307 PMC: 11730532. DOI: 10.1016/j.heliyon.2024.e41355.


Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?.

Wang W, Du Y, Datta S, Fowler J, Sang H, Albadari N Genes Dis. 2025; 12(2):101156.

PMID: 39802403 PMC: 11719324. DOI: 10.1016/j.gendis.2023.101156.